Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 3Phase 1 2Phase NA 1Phase 1/2 1

Status

Active not recruiting 2Enrolling by invitation 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 92Polycystic Ovary Syndrome 10Neoplasm Metastasis 7Carcinoma, Ductal, Breast 5Infertility 4Carcinoma, Lobular 4Osteoporosis 3Neoplasms, Hormone-Dependent 3Neoplasms 3Breast Neoplasms, Male 3Advanced Breast Cancer 3Fallopian Tube Neoplasms 2Carcinoma, Ovarian Epithelial 2Breast Carcinoma In Situ 2Bone Diseases, Metabolic 2Unilateral Breast Neoplasms 1Recurrence 1Peritoneal Neoplasms 1Ovarian Neoplasms 1Osteitis Deformans 1Obesity 1Neoplasms by Site 1Multiple Endocrine Neoplasia Type 1 1Low Grade Serous Ovarian Cancer 1Infertility, Female 1Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer 1Hereditary Sensory and Autonomic Neuropathies 1Hereditary Breast and Ovarian Cancer Syndrome 1HR+/HER2- Breast Cancer 1HER2+ Breast Cancer 1

Interventions

Paclitaxel 20Gemcitabine 16Dexamethasone 16Bevacizumab 16Docetaxel 15Oxaliplatin 14Cyclophosphamide 13Carboplatin 12Capecitabine 12Sorafenib 11Fluorouracil 11Leucovorin 10Cisplatin 10pembrolizumab 9Pemetrexed 9Epoetin Alfa 9venetoclax 8Prednisone 8Fentanyl 8Drug Therapy 8Doxorubicin 8atezolizumab 7Rivaroxaban 7Rituximab 7Darbepoetin alfa 7Anastrozole 7Panitumumab 6Ondansetron 6Morphine 6Irinotecan 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Neoplasms × Letrozole × Clear all
NCT04964934 2026-04-21

SERENA-6

AstraZeneca

Phase 3 Active not recruiting
315 enrolled
Breast

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis, Neoplasms, Neoplasms by Site

NCT04906395 2026-01-13

OVELIA

Tolmar Inc.

Phase 3 Active not recruiting
250 enrolled
Breast

Breast Neoplasms, Neoplasms

NCT05645536 2026-01-12

Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study

Tolmar Inc.

Phase 3 Enrolling by invitation
250 enrolled
Breast

Breast Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡